伊维菌素控制疟疾——一项整群随机试验
在肯尼亚夸莱县疟疾高流行且蚊帐覆盖率高的地区,84个整群共28932名符合条件的参与者按1:1随机分配,每月一次连续3个月接受伊维菌素(400 μg/kg)或阿苯达唑(400 mg)群体给药。5至15岁儿童中,伊维菌素组疟疾感染累积发病率为2.20/儿童年,阿苯达唑组为2.66/儿童年,调整后发病率比为0.74(95%CI 0.58至0.95,P=0.02),严重不良事件发生率两组无显著差异。
要点
- 伊维菌素组疟疾感染发病率为2.20/儿童年,阿苯达唑组为2.66/儿童年,调整后发病率比0.74(95%CI 0.58至0.95,P=0.02)。
- 严重不良事件每100次治疗的发生率两组无显著差异,发病率比0.63(95%CI 0.21至1.91)。
- 在蚊帐高覆盖和使用地区,5至15岁儿童每月一次连续3个月伊维菌素群体给药使疟疾感染发病率较阿苯达唑降低26%。
核心结论
- 在蚊帐高覆盖和高使用的地区,5至15岁儿童每月一次连续3个月接受伊维菌素,疟疾感染发病率较阿苯达唑降低26%,未发现安全性问题。
研究设计与样本
- 在肯尼亚沿海夸莱县开展整群随机试验,该地区疟疾高度流行且驱虫蚊帐覆盖和使用率高。
- 家庭区域整群按1:1随机分配,在短雨季开始时每月一次连续3个月接受伊维菌素(400 μg/kg体重)或阿苯达唑(400 mg,活性对照)群体给药。
- 共84个整群、28932名符合条件的参与者接受随机分组,两组基线特征相似。
- 首轮治疗后的6个月内,每月对5至15岁儿童检测疟疾感染。
- 采用广义估计方程按意向性治疗原则分析,主要结局为疟疾感染累积发病率(5至15岁儿童)和不良事件累积发病率(所有符合条件的参与者)。
主要发现
- 首轮治疗6个月后,伊维菌素组疟疾感染发病率为2.20/儿童年,阿苯达唑组为2.66/儿童年;调整后发病率比(伊维菌素vs阿苯达唑)为0.74(95%CI 0.58至0.95,P=0.02)。
- 每100次治疗的严重不良事件发生率两组无显著差异,发病率比为0.63(95%CI 0.21至1.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic drug that also kills mosquitoes feeding on treated persons, can reduce malaria transmission is unclear. METHODS: We conducted a cluster-randomized trial in Kwale, a county in coastal Kenya in which malaria is highly endemic and coverage and use of insecticide-treated nets are high. Clusters of household areas were randomly assigned in a 1:1 ratio to receive mass administration of ivermectin (400 μg per kilogram of body weight) or albendazole (400 mg, active control) once a month for 3 consecutive months at the beginning of the "short rains" season. Children 5 to 15 years of age were tested for malaria infection monthly for 6 months after the first round of treatment. The two primary outcomes were the cumulative incidence of malaria infection (assessed among children 5 to 15 years of age) and of adverse events (assessed among all eligible participants). Analyses were performed with generalized estimating equations in accordance with the intention-to-treat principle. RESULTS: A total of 84 clusters comprising 28,932 eligible participants underwent randomization. The baseline characteristics of the participants were similar in the trial groups. Six months after the first round of treatment, the incidence of malaria infection was 2.20 per child-year at risk in the ivermectin group and 2.66 per child-year at risk in the albendazole group; the adjusted incidence rate ratio (ivermectin vs. albendazole) was 0.74 (95% confidence interval [CI], 0.58 to 0.95, P = 0.02). The incidence of serious adverse events per 100 treatments did not differ significantly between the trial groups (incidence rate ratio, 0.63; 95% CI, 0.21 to 1.91). CONCLUSIONS: Among children 5 to 15 years of age who were living in an area with high coverage and use of bed nets, ivermectin, administered once a month for 3 consecutive months, resulted in a 26% lower incidence of malaria infection than albendazole. No safety concerns were identified. (Funded by Unitaid; BOHEMIA ClinicalTrials.gov number, NCT04966702; Pan African Clinical Trial Registry number, PACTR202106695877303.).
引用
- Chaccour C, Maia M, Kariuki M, et al. Ivermectin to Control Malaria - A Cluster-Randomized Trial. N Engl J Med. 2025. PMID: 40700688. doi:10.1056/NEJMoa2411262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。